Laddar...
Availability of irinotecan in a second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens
Optimal second-line chemotherapy may contribute to favorable survival in patients who receive first-line treatment for advanced gastric cancer. The aim of this retrospective study was to compare a second-line setting using irinotecan with paclitaxel in terms of survival benefit and safety. A total o...
Sparad:
| Huvudupphovsmän: | , , , , , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
D.A. Spandidos
2011
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3410595/ https://ncbi.nlm.nih.gov/pubmed/22866072 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2011.241 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|